ABBV vs TEM

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Tempus AI Inc. continues to operate in the high-growth, AI-driven precision medicine sector with a vast TAM and a strong strategic vision, bolstered by its proprietary multi-modal data library and recent acquisitions like Ambry. Q1 2026 earnings showed a revenue beat and strong gross margin expansion (63.8%), with exceptional MRD volume growth (+500% YoY), affirming its market position. However, s...